As I was reviewing this months SGLT-2 Therapy edition I was reminded of how much this class of drugs has opened up dialogues on patient care in multiple disease states. With the older diabetes medications we talked A1c, Fasting, or Postprandial; all related to diabetes and there was not much …

When we talk to patients about prediabetes, one of the topics of discussion is likely to be about insulin resistance. However, what we are usually describing is glucose resistance. The lecture usually goes something like this: “If you eat too much sugar, then your cells get filled with the sugar …

In part 4 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about his interest in the comparative analysis of various drug classes and their real-world implications.

In this week's Homerun Slides, understanding the relationship between diabetes and hypertension.

What is insulin resistance? Broadly, insulin resistance can be defined as an abnormal biologic response to insulin; insulin, whether endogenous or exogenous in origin, has limited ability to reverse a hyperglycemic metabolic state.Thus a person with insulin resistance is, almost inevitably, progressing towards developing frank type 2 diabetes (T2DM) if an intervention (usually lifestyle) is not implemented. Due to the very close link between diabetes and insulin resistance, no formal clinical definition of insulin resistance has emerged.We will discuss the potential clinical use of the insulin resistance syndrome and the metabolic syndrome later in the chapter. For now, we focus on investigation of insulin resistance as a useful entity for research concepts, and in particular discuss its biologic consequences by describing its associated risk factor perturbations.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have another exclusive interview from the ADA 2017 Scientific Sessions in San Diego, CA. Dr. Swapnil N. Rajpathak is the Executive Director of the Center for …

In this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Swapnil N. Rajpathak, MD, MPH, DrPH is Executive Director for the Center for Observational and Real World Evidence at Merck.  To view the …

I have recently intensified my cycling training as I prepare for an 80 mile and 6000 foot climbing ride in Chattanooga next month. To get ready I have to switch from riding with our bike club 90% of the time to solo riding with a power meter and heart monitor …

Additional conditions more likely in those diagnosed later in life.

Canagliflozin is found to have reduced risk of cardiovascular death or hospitalization due to heart failure in type 2 diabetes patients.